美股市场个股详情

RNAZ Transcode Therapeutics

添加自选

0.385
+0.005+1.18%

收盘价 11/22 16:00 (美东)

0.387
+0.003+0.75%

盘后 19:28 (美东)

663.86万总市值-444市盈率TTM

Transcode Therapeutics股票讨论区

登录发表评论

已翻译

Trytosaveabit

10/23 06:01

News

$Transcode Therapeutics (RNAZ.US)$ Reuters· just
Transcode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 Ttx-Mc138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Daily Investors

10/22 05:08

SNAP, GNPZ,RNAZ,BNAT

Four companies today that have the potential to explode. GNPX,The first has already exploded, and has warnings from several analysts that it's going to keep going. Next you have SNAP. They have their earnings Today. Named on Zacks as a potential win, and with a History to Blow up. Worth the shot. Next these two companies are the new maxn and muln. They are BNAT && RNAZ. Both Green after a major mountain of interest collapsed, just to tise back up today 🤫

Andy-Lai

10/21 08:22

没人说话哦

$Transcode Therapeutics (RNAZ.US)$

Andy-Lai

10/17 13:24

今天什么情况？

$Transcode Therapeutics (RNAZ.US)$

Andy-Lai

10/17 09:02

今天有可能0.800吗？

$Transcode Therapeutics (RNAZ.US)$

Andy-Lai

10/11 03:58

今天0.750到0.800吗🤣

$Transcode Therapeutics (RNAZ.US)$

Teddy123

10/10 23:44

TransCode Therapeutics完成了对TTX-MC138进行首个群体的阶段1临床试验的初始剂量，这是一项微RNA靶向技术。

$Transcode Therapeutics (RNAZ.US)$
纳斯达克:2024年10月10日，泰科治疗公司（TransCode Therapeutics，Inc.）（NASDAQ: RNAZ），这家致力于使用RNA治疗更有效地治疗癌症的RNA癌症公司，今天宣布已对其第一群体的所有患者进行了第一阶段1a剂量递增临床试验的给药。可治疗候选药正在评估中，TTX-MC138，是泰科的主力候选药，旨在抑制关键的微小RNA-100亿，这是一种对转移性癌症的出现和发展至关重要的微小RNA。所有群体中的患者都已接受了TTX-MC138的第一剂，并继续接受持续治疗。尚未报告任何重大安全问题或剂量限制毒性。

已翻译